Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A 
clinically significant. There were no renal or neurologic adverse events. Valaciclovir was rapidly absorbed and converted to' acyclovir, with plasma valaciclovir levels generally undetectable or levels of <0. 4 ,Ig/ml. After 3 h postdosing, valaciclovir was not detectable in plasma. Acyclovir was measurable in plasma as early as 15 min following valaciclovir dosing, and plasma concentrations of acyclovir greatly exceeded those of valaciclovir. The mean values for the maximum concentration of drug in plasma, time to maximum concentration of drug in plasma, area under the concentration-time curve from 0 h to infinity, and apparent half-life of acyclovir obtained after single-and multiple-dose valaciclovir administration in HIV-infected patients were similar to those reported in normal healthy volunteers. The time to maximum concentration in serum and half-life of acyclovir after valaciclovir administration were approximately 2 and 3 h, respectively, which were similar to those reported after oral administration of acyclovir itself. The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8. 4 ,Lg/ml and 120 h * ,ug/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily. These values were approximately fivefold greater than those achieved with high dosages of oral acyclovir (800 mg, five times daily) and were not affected by continued use of medications necessary for management of advanced HIV disease.
Thus, 2,000 mg of valaciclovir given orally four times daily should be evaluated for its potential efficacy in suppressing cytomegalovirus and other herpes group virus infections not optimally managed with current oral acyclovir therapy.
Valaciclovir (256U87) is the L-valyl ester of acyclovir as the hydrochloride salt and is rapidly converted to acyclovir after oral administration in rats, monkeys, and humans (4, 8, 27) .
Preclinical studies have shown that valaciclovir undergoes extensive first-pass hydrolysis to acyclovir in the liver and intestinal wall, resulting in concentrations of acyclovir in plasma greatly exceeding those of valaciclovir (4, 8) . In animals, valaciclovir is well tolerated, with a safety profile similar to that reported for acyclovir (21) . In healthy human volunteers, multiple oral dosages of valaciclovir (1,000 to 2,000 mg four times daily) produced plasma acyclovir concentrations ranging from three to five times greater than those obtained after high oral dosages of acyclovir (800 mg five times daily) (27) (27) . No serious or unexpected adverse events or laboratory abnormalities were reported for healthy subjects receiving valaciclovir dosages of up to 2,000 mg four times daily for 11 days (27) .
Patients with advanced human immunodeficiency virus (HIV) disease and low absolute CD4 lymphocyte counts are at high risk of developing progressive or recurrent mucocutaneous herpes simplex virus (HSV) or varicella-zoster virus (VZV) infections. The development of progressive mucocutaneous disease caused by acyclovir-resistant HSV and VZV isolates has become a problem of increasing clinical importance, which may be due, in part, to suboptimal chronic oral dosing with acyclovir (10, 15) . Patients with advanced HIV disease are also at risk of developing opportunistic cytomegalovirus (CMV) end-organ disease (25) . Valaciclovir, which produces substantially higher acyclovir levels in plasma than those currently achievable with oral acyclovir therapy, might be effective in preventing both the emergence of acyclovir-resis-tant HSV or VZV disease and the occurrence of CMV disease in HIV-infected patients with low absolute CD4 counts.
The safety and pharmacokinetic data for valaciclovir obtained from phase I studies involving healthy volunteers may not be applicable to patients with advanced HIV disease, who often have clinical or subclinical malabsorption or hepatic or renal impairment, which could affect the pharmacokinetics of valaciclovir. These patients also require concomitant antiretroviral and prophylactic antimicrobial medications which may complicate the pharmacokinetic and safety profiles of valaciclovir. We therefore conducted a phase I trial to evaluate the pharmacokinetics and safety of oral dosages of 1,000 and 2,000 mg of valaciclovir four times daily for 30 days in patients with advanced HIV disease who were being treated with multiple concomitant medications necessary for the management of their disease throughout the study period. Patients were not permitted to take any antiherpetic medication, including acyclovir and interferon, during the week prior to enrollment or during the study period.
MATERIALS AND METHODS
A total of 17 volunteers (14 males and 3 females) were enrolled at two study sites: the San Francisco General Hospital (San Francisco, Calif.; 8 volunteers) and the Johns Hopkins University (Baltimore, Md.; 9 volunteers). Patients were randomly assigned to one of the two valaciclovir dosage regimens at both study sites. Nine patients received 1,000 mg of valaciclovir (cohort 1) and eight patients received 2,000 mg of valaciclovir (cohort 2) four times daily for 30 days. Both study sites enrolled a similar number of patients at each dose level.
Clinical and laboratory evaluation. A complete medical history and physical examination were performed within 14 days prior to enrollment and again at 7 to 10 days after completing the 30-day-study drug-dosing period. Vital signs, review of body systems, and routine hematology, serum chemistry, and urinalysis were examined weekly during the 30-day dosing period and at 7 to 10 days upon completion of the dosing period. Urine CMV cultures at study entry and after 2 and 4 weeks of administration of the study medication were obtained from patients at the San Francisco General Hospital.
Dosing and sampling procedures. The pharmacokinetics of acyclovir and valaciclovir following single-and multiple-dose valaciclovir administration were evaluated on days 1 and 30, respectively. Patients reported to the study site the night before day 1 and remained there throughout the next day. Patients took the first dose of valaciclovir on day 1 at about 7 a.m. after an 8-h fast, and serial blood samples were collected for up to 10 h following dosing. Patients continued to fast for another 3 h postdosing, with fluid intake ad libitum. On days 2 to 29, each patient took the study 'drug four times' daily at approximately 7 a.m., 12 noon, 5 p.m., and 10 p.m. (i.e., at 5-, 5-, 5-, and 9-h intervals per day) on an outpatient basis.'The night before day 30, patients were readmitted to the study site for full pharmacokinetic evaluation as was done on day 1 and remained at the study site until the 24-h-postdosing blood sample was collected.
Blood samples (5 ml each) were collected for measurements of concentrations of acyclovir and'valaciclovir in plasma on day In addition, pharmacokinetic parameter estimates for acyclovir obtained from the HIV-infected patients in this study were compared with those obtained previously from normal healthy volunteers (27) by the Wilcoxon rank sums test. A P value of <0.05 from the nonparametric tests is considered to be statistically significant.
RESULTS
Patient demographics and characteristics. Demographics and baseline characteristics of the HIV-infected patients enrolled in this study are summarized in Table 1 . All patients had normal liver function as shown by the aspartate transaminase and alanine transaminase levels and had normal or minimally impaired renal function as shown by the estimated creatinine clearance rate (63.1 to 115.7 ml/min/1.73 m2). The baseline characteristics were similar among the two groups of patients with regard to age, weight, height, and the advanced stage of HIV disease as indicated by the absolute CD4+ counts and hemoglobin values. Additionally, both cohorts had similar histories of HIV-associated conditions with regard to episodes of candidiasis, Pneumocystis carinii pneumonia, Kaposi's sarcoma, oral hairy leukoplakia, HSV infection, and VZV infection (data not shown). Of note, African-Americans and women were only represented in the 1,000-mg-dose group. Five volunteers reported grade I nausea or diarrhea, and one volunteer reported grade II abdominal pain prior to initiation of study medication (graded per standard National Institute of Allergy and Infectious Diseases criteria).
All patients completed the single-dose phase, and all except two patients completed the multiple-dose phase of the study. One patient in the 2,000-mg-dose group withdrew from the study prematurely because of an adverse experience (neutropenia), and the other patient, in the 1,000-mg-dose group, was withdrawn prematurely because of noncompliance. Compliance with study drug administration was assessed by pill counts of returned study medication containers.
Pharmacokinetics summarizes the median value and range for the ANC and hemoglobin for each cohort at baseline, on days 7, 14, 21, and 30, and at the posttreatment (follow-up) visit. The baseline value for each individual was determined as the average of measurements taken at screening and predose on day 1. In both cohorts, the median values for hemoglobin were similar at baseline and the posttreatment visit. In cohort 1, the median ANC values were slightly lower during the posttreatment period than at baseline, whereas in cohort 2 the median ANC Concomitant medications. All patients were being treated with some medication for prophylaxis against P. carinii pneumonia. The use of concomitant medications for HIV disease was similar in both cohorts. All but two patients were taking antiretroviral medications prior to study entry. As shown in Table 1 , seven patients in cohort 1 and three patients in cohort 2 were taking zidovudine, and one patient in cohort 1 and three patients in cohort 2 were taking either didanosine or dideoxycytosine. One patient was on combination therapy of zidovudine and dideoxycytosine. An additional patient was on zidovudine or didanosine as a study drug in a blinded clinical trial.
DISCUSSION
In patients with advanced HIV disease, the kinetics of acyclovir disposition after multiple doses of 1,000 or 2,000 mg of valaciclovir (four times daily) was unchanged compared with that after single-dose administration. Estimates of the acyclovir pharmacokinetic parameters (Cm., Tm[, AUCO,, and T1,2) obtained for the HIV-infected patients were similar to those reported in a phase I valaciclovir study of normal healthy volunteers. These results suggest that the pharmacokinetics of acyclovir following multiple oral administration of valaciclovir is unaltered in patients with advanced HIV disease who also received multiple concomitant medications.
The steady-state peak and trough acyclovir concentrations and daily acyclovir AUC values obtained after administration of 1,000 and 2,000 mg of valaciclovir four times daily were approximately three to five times greater than those observed previously after high oral doses of acyclovir (800 mg five times daily) and were comparable to those observed after intravenous doses of acyclovir (5 to 10 mg/kg every 8 h) in patients with normal renal function (3, 7) . In addition, the intersubject variability in concentrations of acyclovir in plasma following administration of valaciclovir was lower than that after administration of acyclovir itself (CV for AUC, <30% versus 40%) (27 ,ul occurred in three (19%) individuals (two in the 1,000-mgdose group and one in the 2,000-mg-dose group), all of whom recovered after valaciclovir was discontinued (Table 5) . Of note, one of these three individuals was concomitantly receiving zidovudine. In addition, one patient who was rechallenged with 2,000 mg of valaciclovir for 7 days did not have a decreased ANC. Previous studies of high doses of oral and intravenous acyclovir in immunocompromised patients, including those with advanced HIV disease, have not reported myelosuppression as an adverse experience (2, 5, 6, 11, 20) . In addition, acyclovir is not toxic to bone marrow progenitor cells in vitro (19) . However, it is known that patients with advanced HIV disease frequently become neutropenic, because of a variety of etiologies including the common use of myelosuppressive drugs and other AIDS-related opportunistic infections and malignancies as well as a possible direct effect of HIV on myeloid precursors (28) . An actively controlled trial of valaciclovir in advanced HIV disease, currently being conducted, should determine if the neutropenia observed in this phase I trial was due to an effect of high doses of valaciclovir or acyclovir exposure, concomitant medications, or other factors related to HIV disease.
